Table 1.
Demographics, clinical characteristics, and laboratory analysis of LN patients.
| LN-B-cell | LN-non-B-cell | P value | |
|---|---|---|---|
| n = 118 | n = 74 | ||
| Sex (male/female) | 17/101 | 8/66 | 0.513 |
| Age (years) | 34 ± 13 | 33 ± 13 | 0.526 |
| SLE duration (months) | 57 ± 60 | 43 ± 63 | 0.294 |
| LN duration (months) | 25 ± 37 | 26 ± 49 | 0.852 |
| SLEDAI | 14 ± 6 | 13 ± 5 | 0.042 |
| Proteinuria (g/24 h) | 3.13 ± 2.97 | 2.69 ± 2.56 | 0.311 |
| Blood urea nitrogen (mmol/L) | 10.43 ± 7.67 | 6.24 ± 3.40 | 0.000 |
| Serum creatinine (μmol/L) | 89.91 ± 66.89 | 59.75 ± 22.05 | 0.000 |
| Serum C3 (g/L) | 0.51 ± 0.21 | 0.54 ± 0.26 | 0.427 |
| Serum C4 (g/L) | 0.082 ± 0.049 | 0.084 ± 0.076 | 0.827 |
| Anti-dsDNA (positive/negative)† | 72/11 | 44/9 | 0.506 |
†Anti-dsDNA antibodies were not detected in 35 patients in the LN-B-cell group and 21 patients in LN-non-B-cell group.
SLEDAI: systemic lupus erythematosus disease activity index; SLE: systemic lupus erythematosus; LN: lupus nephritis; anti-dsDNA: anti-double-stranded DNA antibody.